Press Releases

REDWOOD CITY, Calif. , July 24, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the sale of one of its non-strategic subsidiaries, NeoForce, Inc.

Positive guidance received on key elements of Phase III program Company expects to initiate pivotal Phase III clinical trial by year-end 2017 DCCR has orphan designation for the treatment of PWS in the US REDWOOD CITY, Calif. , July 05, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc.

Completed merger with Essentialis, Inc. and concurrent financing of $10 million New company name, Soleno Therapeutics, Inc. , to reflect new strategic focus on rare disease therapeutics; stock to trade under NASDAQ ticker symbol “SLNO” Scientific advice being obtained from the U.S.

REDWOOD CITY, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016 .

Lead Clinical Asset Entering Phase II/III Development in 2017 for the  Treatment of Prader-Willi Syndrome Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones REDWOOD CITY, Calif. , March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc.

REDWOOD CITY, Calif. , Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive

Combined Company to Focus on Advancing Novel, Late-Stage Asset for the Treatment of Prader-Willi Syndrome, a Devastating, Orphan Disease  Enrollment in a Phase II/III Clinical Trial Expected to Begin in Second Half of 2017 $8 Million Concurrent Financing; Sufficient to Fund Development Plan Through

REDWOOD CITY, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced financial results for the third quarter ended

REDWOOD CITY, Calif. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive

Strong Consumer Feedback from Pilot Serenz Sales in the UK REDWOOD CITY, Calif. , Aug. 12, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today